1623 Capital’s Health Catalyst HCAT Stock Holding History

1623 Capital’s Portfolio HCAT Stock Details HCAT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	–	Sell	-15,918	Closed	-$631K	–	59
2021 Q4	$631K	Buy	+15,918	New	+$725K	0.24%	49

Other funds holding HCAT

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return

Aberdeen Group Edinburgh, United Kingdom $61.9B AUM 29.81% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Riverbridge Partners Minneapolis, Minnesota $3.58B AUM 4.02% 1-Year Est. Return

1623 Capital's HCAT Position: Q1 2022 in Review

1623 Capital sold out of Health Catalyst (HCAT) in Q1 2022, closing a stake of 15,918 shares — an estimated $631K sold.

1623 Capital first reported a position in HCAT in Q4 2021 and held it in 1 quarter. The position peaked at $631K in Q4 2021. 185 funds tracked by Wall St. Rank hold HCAT as of Q1 2022.

1623 Capital reported no remaining Health Catalyst position as of Q1 2022 after selling out during the quarter.
1623 Capital sold 15,918 Health Catalyst shares in Q1 2022, an estimated $631K.
1623 Capital first reported a position in Health Catalyst in Q4 2021 and held it in 1 quarter.
1623 Capital's Health Catalyst position peaked at $631K in Q4 2021.
185 funds tracked by Wall St. Rank held Health Catalyst as of Q1 2022.

Based on 1623 Capital's 13F filing for Q1 2022, filed 13 May 2022.